Alluvi, previously BI 4744, offers a significant development in obesity therapy. This dual agonist targeting both GLP-1 and GIP targets demonstrates compelling efficacy in patient assessments, potentially exceeding https://alluvi-peptides507052.articlesblogger.com/65793228/alluvi-a-comprehensive-investigation-into-the-retatrutide-s-possibilities